CervoMed Announces Alignment with FDA on Registration Path for Neflamapimod in Dementia with Lewy Bodies GlobeNewswire November 04, 2025 FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is advancing preparations for global pivotal trial initiation […]

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update GlobeNewswire November 04, 2025 — Third quarter 2025 net product revenue from global sales of IMCIVREE(R) (setmelanotide) of $51.3 million — — December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity — — Company is on track to

Yukon Metals Launches Digital Marketing Campaign GlobeNewswire November 04, 2025 View PDF Version VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) — Yukon Metals Corp. (CSE: YMC, FSE: E770, OTCQB: YMMCF) (“Yukon Metals” or the “Company) has entered into a service agreement with Native Ads, Inc. (“Native Ads”) dated October 29, 2025 (the “Agreement”), pursuant

Chicago Atlantic Real Estate Finance Announces Third Quarter 2025 Financial Results GlobeNewswire November 04, 2025 CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced its results for the quarter ended September 30, 2025. Peter Sack,

Verano Holdings Corp. Completes Redomicile of Parent Company from British Columbia to Nevada GlobeNewswire November 04, 2025 CHICAGO, Nov. 04, 2025 (GLOBE NEWSWIRE) — Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the completion of its previously announced plan to redomicile Verano Holdings Corp.

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update GlobeNewswire November 04, 2025 Enrollment and dosing completed in KT-621 (STAT6) BroADen Phase 1b trial in atopic dermatitis (AD) patients, with data to be reported in December 2025 Initiated KT-621 BROADEN2 Phase 2b trial in AD KT-621 BREADTH Phase 2b trial in

Maze Therapeutics to Participate in Four Upcoming Investor Conferences GlobeNewswire November 04, 2025 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) — Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor

Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire November 04, 2025 Third-quarter 2025 Rezdiffra(TM) (resmetirom) net sales of $287.3 million As of September 30, 2025, more than 29,500 patients on Rezdiffra Closed global licensing agreement with CSPC Pharma to add oral GLP-1 to pipeline New Orange Book listed patent for Rezdiffra

AmpliTech Group To Release Q3 – 2025 Earnings On November 14th Before Market Opening – Also Announces Investor's Conference Call GlobeNewswire November 04, 2025 HAUPPAUGE, N.Y., Nov. 04, 2025 (GLOBE NEWSWIRE) — AmpliTech Group, Inc (Nasdaq: AMPG, AMPGW), a designer, developer, and manufacturer of state-of-the-art signal processing components for satellite, Public and Private ORAN 5G,

Abcourt Announces Arrangements for Upcoming Annual Meeting of Shareholders in Event of Canada Post Service Disruption GlobeNewswire November 04, 2025 ROUYN-NORANDA, Quebec, Nov. 04, 2025 (GLOBE NEWSWIRE) — Abcourt Mines Inc. (TSXV: ABI) (OTCQB: ABMBF) (“Abcourt” or the “Corporation“) wishes to update its shareholders regarding the Corporation's upcoming annual meeting, which is to be held